176 related articles for article (PubMed ID: 14999954)
1. An ounce of prevention. Drugs used to treat hyperlipidemia (Part 1).
Turkoski BB
Orthop Nurs; 2004; 23(1):58-61. PubMed ID: 14999954
[TBL] [Abstract][Full Text] [Related]
2. An ounce of prevention. Drugs used to treat hyperlipidemia (Part 2).
Turkoski B
Orthop Nurs; 2004; 23(3):184-9. PubMed ID: 15211899
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology department: pharmacologic approaches to abnormal blood lipids.
Gylys KH
J Cardiovasc Nurs; 2000 Jan; 14(2):9-15. PubMed ID: 10653272
[TBL] [Abstract][Full Text] [Related]
4. Choosing the right lipid-regulating agent. A guide to selection.
Farmer JA; Gotto AM
Drugs; 1996 Nov; 52(5):649-61. PubMed ID: 9118815
[TBL] [Abstract][Full Text] [Related]
5. Management of protease inhibitor-associated hyperlipidemia.
Penzak SR; Chuck SK
Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
[TBL] [Abstract][Full Text] [Related]
6. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Perreault S; Hamilton VH; Lavoie F; Grover S
Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
[TBL] [Abstract][Full Text] [Related]
7. Current, new and future treatments in dyslipidaemia and atherosclerosis.
Chong PH; Bachenheimer BS
Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
[TBL] [Abstract][Full Text] [Related]
8. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
Borgia MC; Medici F
Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
[TBL] [Abstract][Full Text] [Related]
9. Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
Olivier P; Plancke MO; Marzin D; Clavey V; Sauzieres J; Fruchart JC
Atherosclerosis; 1988 Mar; 70(1-2):107-14. PubMed ID: 3162679
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
Shepherd J; Betteridge J; Van Gaal L;
Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866
[TBL] [Abstract][Full Text] [Related]
11. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Schiel R; Bambauer R; Müller UA
Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
[TBL] [Abstract][Full Text] [Related]
12. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.
Spencer CM; Barradell LB
Drugs; 1996 Jun; 51(6):982-1018. PubMed ID: 8736620
[TBL] [Abstract][Full Text] [Related]
13. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Brown WV
Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
[TBL] [Abstract][Full Text] [Related]
14. Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.
Jacobson TA
Curr Atheroscler Rep; 2001 Sep; 3(5):373-82. PubMed ID: 11487448
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
Hay JW; Sterling KL
Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
[TBL] [Abstract][Full Text] [Related]
16. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
Najib J
Clin Ther; 2002 Dec; 24(12):2022-50. PubMed ID: 12581543
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
Jen SL; Chen JW; Lee WL; Wang SP
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
[TBL] [Abstract][Full Text] [Related]
18. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
19. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
20. Should pediatric patients with hyperlipidemia receive drug therapy?
Bhatnagar D
Paediatr Drugs; 2002; 4(4):223-30. PubMed ID: 11960511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
